BioDelivery Sciences International Inc. (BDSI) June 9 announced that the Food and Drug Administration has approved Bunavail (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence.
BDSI said Bunavail should be used as part of a complete treatment plan to include counseling and psychosocial support. The company said it expects to launch the drug late in the third quarter.
Bunavail was designed using BDSI’s advanced drug delivery technology, BioErodible MucoAdhesive (BEMA), allowing for the efficient and convenient delivery of buprenorphine while potentially overcoming some of the administration challenges presented by the sublingual (under the tongue) dosage ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.